About us
Schering AG is a research-based pharmaceutical and biotechnology company. Its activities are focused on four business areas: gynaecology & andrology, diagnostics imaging & radiopharmaceuticals, dermatology, and specialized therapeutics for chronic and disabling diseases relating to the central nervous system, oncology and the cardiovascular system.
Using interdisciplinary networks it builds bridges to academic researchers around the world, as well as to highly specialized biotech pioneers and partners in the pharmaceutical industry. Schering combines its own long-standing medical and pharmaceutical expertise with the latest discoveries from genomic research. Throughout, its research focuses on a meaningful combination of early diagnosis, prevention, treatment and therapy control.
| This site is provided by Schering AG, Germany, represented by the Executive Board: |
|
Hubertus Erlen (Chairman) |
Marc Rubin |
|
Ulrich Köstlin |
Jörg Spiekerkötter |
|
Lutz Lingnau |
Günter Stock |
Postal address:
Schering AG
D-13342 Berlin,
Germany
Email: testogel@schering.de |
Registered trading seat: Berlin
Trade register: AG Charlottenburg 93 HRB 283
Registration number: DE 136.563.568 |
|